Despite recommendations suggesting that biological and targeted synthetic disease-
modifying antirheumatic drugs (b/tsDMARDs) should be used in combination with …

Background Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid
arthritis. The Oral Rheumatoid Arthritis triaL (ORAL) Strategy aimed to assess the …

Objectives Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid
arthritis (RA). We report an integrated safety summary of tofacitinib from two phase I, nine …

Background Final data are presented for the ORAL Sequel long-term extension (LTE) study
evaluating the safety and efficacy of tofacitinib 5 mg and 10 mg twice daily (BID) for up to 9.5 …

Introduction Rheumatic diseases are autoimmune, inflammatory diseases often associated
with cardiovascular (CV) disease, a major cause of mortality in these patients. In recent …

Objectives. Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. The aim of
this analysis was to characterize changes in haematological parameters following tofacitinib …

Introduction Post-marketing surveillance (PMS) is an integral part of monitoring adverse
events (AEs) following approval of new drugs. Tofacitinib is an oral Janus kinase inhibitor for …

Objective Tofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA).
This study was undertaken to evaluate the risk of major adverse cardiovascular events …

Objective The risk of cardiovascular disease (CVD) is higher in patients with psoriatic
arthritis (PsA) compared to the general population. Tofacitinib is an oral Janus kinase …

Objective To provide the first direct comparison of patient-reported outcomes (PROs)
following treatment with tofacitinib monotherapy versus tofacitinib or adalimumab (ADA) in …